Log In
BCIQ
Print this Print this
 

Natura-alpha (TAK-114)

  Manage Alerts
Collapse Summary General Information
Company Natrogen Therapeutics Intl. Inc.
DescriptionOral small-molecule that inhibits expression of interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
PartnerTakeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today